Clinical Guidelines

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Share

A 54-year-old African American woman, Ms. Jones, with a newly diagnosed immunoglobulin A lambda monoclonal gammopathy of undetermined significance (MGUS), presents with worsening neuropathy. With a history of type 2 diabetes and hypertension, she undergoes further workup which shows intermediate-risk MGUS and a 37% progression risk to multiple myeloma over 20 years. After thorough discussion about treatment options, Ms. Jones opts for monitoring her condition instead of immediate biopsy. Key findings on MGUS include its asymptomatic nature, risk stratification, and necessity for ongoing observation.

Original Source(s)

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • by Kimberly Noonan, DNP, ANP-BC, AOCN, FAAN, Kevin Brigle, PhD, ANP, Charise Gleason, MSN, NP-C, AOCNP, Carrie Bellerive, BS, RN, BMTCN, Mary Steinbach, DNP, APRN, Deborah Doss, RN, OCN

  • March 4, 2026

Related Content

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

AML Complexity Uncovered: A Unified Whole Genome and Informatics Approach for High Resolution Disease Understanding

Standard-of-care (SOC) genomic testing in acute myeloid leukemia (AML) has historically resulted in fragmented, incomplete genomic profiles that mask clinically significant biology.

  • March 12, 2026

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...